News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
883,867 Results
Type
Article (88781)
Company Profile (816)
Press Release (794248)
Multimedia
Podcasts (238)
Webinars (35)
Section
Business (233593)
Career Advice (4162)
Deals (39989)
Drug Delivery (177)
Drug Development (91704)
Employer Resources (207)
FDA (18553)
Job Trends (17487)
News (398734)
Policy (40013)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (3053)
Academic (2)
Accelerated approval (56)
ADA (49)
Adcomms (40)
Allergies (198)
Alliances (56990)
ALS (236)
Alzheimer's disease (1969)
Antibody-drug conjugate (ADC) (552)
Approvals (18895)
Artificial intelligence (868)
ASCO (345)
Autoimmune disease (362)
Automation (64)
Bankruptcy (407)
Best Places to Work (12635)
BIOSECURE Act (23)
Biosimilars (248)
Biotechnology (480)
Bladder cancer (211)
Brain cancer (85)
Breast cancer (838)
Cancer (6579)
Cardiovascular disease (554)
Career advice (3597)
Career pathing (52)
CAR-T (385)
CDC (76)
Celiac Disease (3)
Cell therapy (1071)
Cervical cancer (54)
Clinical research (79011)
Collaboration (2371)
Company closure (8)
Compensation (1512)
Complete response letters (106)
COVID-19 (3041)
CRISPR (124)
C-suite (1285)
Cystic fibrosis (167)
Data (8694)
Decentralized trials (3)
Denatured (91)
Depression (193)
Dermatology (97)
Diabetes (703)
Diagnostics (7600)
Digital health (70)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (425)
Drug pricing (245)
Drug shortages (39)
Duchenne muscular dystrophy (318)
Earnings (102484)
Editorial (78)
Employer branding (25)
Employer resources (174)
Events (138663)
Executive appointments (1192)
FDA (22622)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (36)
Funding (1945)
Gene editing (271)
Generative AI (89)
Gene therapy (849)
GLP-1 (1286)
Government (5560)
Grass and pollen (8)
Guidances (420)
Healthcare (21263)
Hematology (198)
HIV (95)
Huntington's disease (64)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (353)
Immuno-oncology (116)
Indications (206)
Infectious disease (3439)
Inflammatory bowel disease (242)
Inflation Reduction Act (17)
Influenza (148)
Intellectual property (323)
Interviews (821)
IPO (18003)
IRA (61)
Job creations (5209)
Job search strategy (2871)
JPM (73)
Kidney cancer (23)
Labor market (122)
Layoffs (687)
Leadership (53)
Legal (10171)
Liver cancer (111)
Longevity (37)
Lung cancer (873)
Lymphoma (470)
Machine learning (66)
Management (66)
Manufacturing (1221)
MASH (226)
Medical device (15279)
Medtech (15438)
Mergers & acquisitions (23290)
Metabolic disorders (1822)
mRNA (266)
Multiple sclerosis (204)
NASH (24)
Neurodegenerative disease (508)
Neuropsychiatric disorders (126)
Neuroscience (3716)
Neurotech (2)
NextGen: Class of 2026 (7716)
Non-profit (5146)
Now hiring (80)
Obesity (871)
Opinion (374)
Ovarian cancer (244)
Pain (285)
Pancreatic cancer (352)
Parkinson's disease (417)
Partnered (39)
Patents (655)
Patient recruitment (763)
Peanut (70)
People (67999)
Pharmaceutical (136)
Pharmacy benefit managers (37)
Phase 1 (24420)
Phase 2 (34316)
Phase 3 (25808)
Pipeline (9752)
Policy (398)
Postmarket research (3560)
Preclinical (10981)
Press Release (72)
Prostate cancer (347)
Psychedelics (68)
Radiopharmaceuticals (373)
Rare diseases (1263)
Real estate (7462)
Recruiting (81)
Regulatory (30386)
Reports (77)
Research institute (2771)
Resumes & cover letters (654)
Rett syndrome (43)
RNA editing (29)
RSV (98)
Schizophrenia (196)
Series A (327)
Series B (237)
Service/supplier (28)
Sickle cell disease (127)
Special edition (32)
Spinal muscular atrophy (190)
Sponsored (55)
Startups (4372)
State (2)
Stomach cancer (21)
Supply chain (146)
Tariffs (104)
The Weekly (144)
Vaccines (1306)
Venture capital (134)
Weight loss (597)
Women's health (141)
Worklife (24)
Date
Today (95)
Last 7 days (640)
Last 30 days (3214)
Last 365 days (33227)
2026 (16230)
2025 (33218)
2024 (38123)
2023 (42564)
2022 (53928)
2021 (58720)
2020 (57663)
2019 (51334)
2018 (39119)
2017 (37188)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1297)
Alabama (102)
Alaska (7)
Arizona (403)
Arkansas (16)
Asia (52300)
Australia (9193)
California (14380)
Canada (4014)
China (1574)
Colorado (618)
Connecticut (641)
Delaware (443)
Europe (120605)
Florida (2132)
Georgia (467)
Hawaii (4)
Idaho (70)
Illinois (1253)
India (102)
Indiana (664)
Iowa (25)
Japan (594)
Kansas (143)
Kentucky (56)
Louisiana (64)
Maine (89)
Maryland (1744)
Massachusetts (10520)
Michigan (422)
Minnesota (800)
Mississippi (7)
Missouri (164)
Montana (37)
Nebraska (30)
Nevada (153)
New Hampshire (92)
New Jersey (3811)
New Mexico (35)
New York (3783)
North Carolina (1939)
North Dakota (11)
Northern California (7151)
Ohio (449)
Oklahoma (27)
Oregon (55)
Pennsylvania (2832)
Puerto Rico (30)
Rhode Island (54)
South America (1668)
South Carolina (88)
South Dakota (2)
Southern California (5640)
Tennessee (228)
Texas (2343)
United States (51451)
Utah (427)
Vermont (1)
Virginia (364)
Washington D.C. (89)
Washington State (1183)
West Virginia (4)
Wisconsin (160)
Wyoming (2)
There are 883,867 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
June 12, 2026
·
7 min read
Press Releases
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
June 12, 2026
·
4 min read
Press Releases
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
June 12, 2026
·
12 min read
Press Releases
Cepheid Delivers Xpert® Hemorrhagic Fever Panel Tests to Africa to Address Diagnostic Gaps in Ebola Bundibugyo Outbreak
June 12, 2026
·
5 min read
Press Releases
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
June 12, 2026
·
11 min read
Press Releases
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
June 12, 2026
·
7 min read
Rare diseases
Amgen shores up Tavneos’ FDA defense with Duke data analysis
After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.
June 12, 2026
·
2 min read
·
Tristan Manalac
Press Releases
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
June 12, 2026
·
11 min read
Press Releases
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
June 12, 2026
·
11 min read
Neurodegenerative disease
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
June 12, 2026
·
2 min read
·
Tristan Manalac
1 of 88,387
Next
